Pharmaceutical company Dimethaid Research Inc plans to market their osteoarthritis drug 'Pennsaid' in Guyana.

A Canada NewsWire release says Dimethaid signed an agreement with In2Focus Sales Development Services Ltd, to market Pennsaid throughout the United Kingdom and in the Caribbean including Guyana.

According to the release, In2Focus Sales Development filed a new series of regulatory applications in the Bahamas, Bermuda, Guyana, Jamaica and Trinidad and Tobago as part of an ongoing programme to increase marketing opportunities for Pennsaid.

Officials from the Food and Drug Administration last week said no such company has filed a regulatory application.

'Pennsaid' is a therapy for patients suffering from osteoarthritis of the knee.

"Pennsaid is quickly becoming a first-choice therapy for patients with osteoarthritis of the knee," noted Danny Dean, director of national sales and marketing at Dimethaid.

Fazeel Farose, executive manager of Twins Pharmaceutical said if the drug is cleared for marketing in Guyana, providing the price is right, he would like to sell it.

Farose stated that in Guyana a number of individuals have knee complaints and the drug would have a good market.

He added that the price would also determine if doctors will prescribe the drug for patients covered by the National Insurance Scheme (NIS).